Mark C. Johnson
Senior director, Investor Relations
Mark Johnson currently serves as senior director, Investor Relations for aTyr Pharma, Inc., a publicly traded biopharmaceutical company in San Diego. aTyr is engaged in the discovery and clinical development of innovative medicines using its knowledge of tRNA synthetase biology. aTyr’s clinical stage ATYR1923 therapeutic product candidate is designed to temper immune engagement to slow the progression of severe interstitial lung diseases.
In Johnson’s role he is charged with communicating the aTyr story to Wall Street investors, analysts and bankers. In addition, he works directly with executive management and the board of directors on strategic and corporate finance initiatives.
Previously, Johnson worked as director of Investor Relations for SoftBank Group, a $100 billion market cap technology conglomerate headquartered in Tokyo, Japan. There he led all U.S.-based investor relations activities out of the San Francisco area. Before that he worked at DeNA, a successful Japanese internet company also based in Tokyo.
Johnson started his career in San Diego at another biopharmaceutical company, MediciNova, which is developing new treatments for patients with multiple sclerosis, idiopathic pulmonary fibrosis and acute exacerbations from asthma and COPD.
Johnson has a MBA from UCSD’s Rady school and a BA in Economics from Cornell University. He is currently a 2018 level III candidate in the CFA program.